Data / Drug companies / Regadenoson
Regadenoson: 14 companies and 15 products in the FDA NDC directory
Regadenoson is listed in the FDA National Drug Code Directory by 14 companies, with 15 products in commercial distribution. 14 of the products (93.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, solution; injection, and the newest product started marketing on April 3, 2025.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 14
- Products
- 15
- Generic (ANDA) products
- 14 (93.3%)
- Application numbers
- 12
- Routes
- Intravenous
- Brand names
- Lexiscan
- openFDA record search
- api.fda.gov
Companies that list regadenoson
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Apotex Corp. | 2 | injection, solution | Generic drugs (ANDA) | April 3, 2025 |
| Accord Healthcare Inc. | 1 | injection, solution | Generic drugs (ANDA) | March 10, 2023 |
| Astellas Pharma US, Inc. | 1 | injection, solution | New drug applications (NDA) | April 10, 2008 |
| Baxter Healthcare Corporation | 1 | injection, solution | Generic drugs (ANDA) | May 23, 2023 |
| Dr. Reddy's Laboratories Inc. | 1 | injection | Generic drugs (ANDA) | April 23, 2023 |
| Eugia US LLC | 1 | injection | Generic drugs (ANDA) | October 26, 2022 |
| Gland Pharma Limited | 1 | injection, solution | Generic drugs (ANDA) | July 12, 2022 |
| Hikma Pharmaceuticals USA Inc. | 1 | injection, solution | Generic drugs (ANDA) | April 3, 2023 |
| Hospira, Inc. | 1 | injection, solution | Generic drugs (ANDA) | March 1, 2023 |
| Indies Pharma Jamaica Limited | 1 | injection, solution | Generic drugs (ANDA) | August 22, 2024 |
| International Medication Systems, Limited | 1 | injection, solution | Generic drugs (ANDA) | April 20, 2023 |
| Kanchan Healthcare Inc | 1 | injection, solution | Generic drugs (ANDA) | August 22, 2024 |
| Marlex Pharmaceuticals, Inc. | 1 | injection, solution | Generic drugs (ANDA) | August 22, 2024 |
| Meitheal Pharmaceuticals Inc. | 1 | injection, solution | Generic drugs (ANDA) | April 11, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 13 | 86.7% |
| Injection | 2 | 13.3% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 14 | 93.3% |
| New drug applications (NDA) | 1 | 6.7% |
Pharmacologic classes
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.